FibroGen Inc.'s pamrevlumab in a phase 2b study was able to slow the progression of a certain lung disease.
The study, named Praise, compared pamrevlumab to placebo in patients with idiopathic pulmonary fibrosis, a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As tissue scarring progresses, transfer of oxygen into the bloodstream is increasingly impaired, leading to irreversible loss of lung function.
In addition, the study's results were found to be consistent with results reported from a previous phase 2 study in patients with idiopathic pulmonary fibrosis.
FibroGen used quantitative lung fibrosis, or QLF, measurements to evaluate the change in lung fibrosis captured by high resolution computed tomography, a noninvasive imaging tool.
The change in QLF volumes in pamrevlumab-treated patients over 48 weeks was significantly less than in patients on placebo, and the treatment difference between pamrevlumab versus placebo was observed as early as six months.
Pamrevlumab has also grabbed the fast-track designation from the U.S. Food and Drug Administration in its treatment for pancreatic cancer.
San Francisco, Calif.-based FibroGen is a research-based biopharmaceutical company, which discovers, develops and commercializes therapeutic agents to treat serious, unmet medical needs in the U.S.